Figure 3.

Prednisolone exerts a mild overall effect on bone mass, formation, and resorption

(A) Representative micro-CT images of the distal femur in AAV8-Control-treated mice after 28 days of placebo or prednisolone treatment. Scale bar = 1 mm.

(B) Cortical thickness (Cort Th) and (C) Cortical porosity (Cort porosity, one outlier removed from placebo + AAV8-Ostn group) were measured at the femoral mid-diaphysis.

(D) Representative force-displacement curves from three-point flexural testing of femurs.

(E) Ultimate stress and (F) work to yield were calculated from force-displacement curves from each sample and moment of inertia measured on the same bones.

(G) Trabecular bone mineral density (Trab BMD, one outlier removed from placebo + AAV8-Control group) and (H) Trabecular thickness (Trab Th) were measured in the distal femoral metaphysis.

(I) Serum biomarker of bone formation, procollagen type 1 N-terminal peptide (P1NP, one outlier removed from prednisolone + AAV8-Ostn group).

(J) Serum biomarker of bone formation, C-terminal collagen crosslinks (CTX). n = 7-10. ∗p < 0.05 compared to the corresponding placebo group by Sidak’s multiple comparisons tests. All error bars show +/− SD.